Literature DB >> 25233440

Hepatic CREB3L3 controls whole-body energy homeostasis and improves obesity and diabetes.

Yoshimi Nakagawa1, Aoi Satoh, Sachiko Yabe, Mika Furusawa, Naoko Tokushige, Hitomi Tezuka, Motoki Mikami, Wakiko Iwata, Akiko Shingyouchi, Takashi Matsuzaka, Shiori Kiwata, Yuri Fujimoto, Hidehisa Shimizu, Hirosuke Danno, Takashi Yamamoto, Kiyoaki Ishii, Tadayoshi Karasawa, Yoshinori Takeuchi, Hitoshi Iwasaki, Masako Shimada, Yasushi Kawakami, Osamu Urayama, Hirohito Sone, Kazuhiro Takekoshi, Kazuto Kobayashi, Shigeru Yatoh, Akimitsu Takahashi, Naoya Yahagi, Hiroaki Suzuki, Nobuhiro Yamada, Hitoshi Shimano.   

Abstract

Transcriptional regulation of metabolic genes in the liver is the key to maintaining systemic energy homeostasis during starvation. The membrane-bound transcription factor cAMP-responsive element-binding protein 3-like 3 (CREB3L3) has been reported to be activated during fasting and to regulate triglyceride metabolism. Here, we show that CREB3L3 confers a wide spectrum of metabolic responses to starvation in vivo. Adenoviral and transgenic overexpression of nuclear CREB3L3 induced systemic lipolysis, hepatic ketogenesis, and insulin sensitivity with increased energy expenditure, leading to marked reduction in body weight, plasma lipid levels, and glucose levels. CREB3L3 overexpression activated gene expression levels and plasma levels of antidiabetic hormones, including fibroblast growth factor 21 and IGF-binding protein 2. Amelioration of diabetes by hepatic activation of CREB3L3 was also observed in several types of diabetic obese mice. Nuclear CREB3L3 mutually activates the peroxisome proliferator-activated receptor (PPAR) α promoter in an autoloop fashion and is crucial for the ligand transactivation of PPARα by interacting with its transcriptional regulator, peroxisome proliferator-activated receptor gamma coactivator-1α. CREB3L3 directly and indirectly controls fibroblast growth factor 21 expression and its plasma level, which contributes at least partially to the catabolic effects of CREB3L3 on systemic energy homeostasis in the entire body. Therefore, CREB3L3 is a therapeutic target for obesity and diabetes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25233440     DOI: 10.1210/en.2014-1113

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  22 in total

1.  Lysine Acetylation of CREBH Regulates Fasting-Induced Hepatic Lipid Metabolism.

Authors:  Hyunbae Kim; Roberto Mendez; Xuequn Chen; Deyu Fang; Kezhong Zhang
Journal:  Mol Cell Biol       Date:  2015-10-05       Impact factor: 4.272

2.  CREBH normalizes dyslipidemia and halts atherosclerosis in diabetes by decreasing circulating remnant lipoproteins.

Authors:  Masami Shimizu-Albergine; Debapriya Basu; Jenny E Kanter; Farah Kramer; Vishal Kothari; Shelley Barnhart; Carissa Thornock; Adam E Mullick; Noemie Clouet-Foraison; Tomas Vaisar; Jay W Heinecke; Robert A Hegele; Ira J Goldberg; Karin E Bornfeldt
Journal:  J Clin Invest       Date:  2021-11-15       Impact factor: 14.808

Review 3.  Transcriptional and Chromatin Regulation during Fasting - The Genomic Era.

Authors:  Ido Goldstein; Gordon L Hager
Journal:  Trends Endocrinol Metab       Date:  2015-10-29       Impact factor: 12.015

4.  Hepatic Sel1L-Hrd1 ER-associated degradation (ERAD) manages FGF21 levels and systemic metabolism via CREBH.

Authors:  Asmita Bhattacharya; Shengyi Sun; Heting Wang; Ming Liu; Qiaoming Long; Lei Yin; Sander Kersten; Kezhong Zhang; Ling Qi
Journal:  EMBO J       Date:  2018-11-02       Impact factor: 11.598

Review 5.  The transcription factors CREBH, PPARa, and FOXO1 as critical hepatic mediators of diet-induced metabolic dysregulation.

Authors:  Zhao Yang; Katherine Roth; Manisha Agarwal; Wanqing Liu; Michael C Petriello
Journal:  J Nutr Biochem       Date:  2021-03-28       Impact factor: 6.117

6.  Intestinal CREBH overexpression prevents high-cholesterol diet-induced hypercholesterolemia by reducing Npc1l1 expression.

Authors:  Takuya Kikuchi; Kana Orihara; Fusaka Oikawa; Song-Iee Han; Motoko Kuba; Kanako Okuda; Aoi Satoh; Yoshinori Osaki; Yoshinori Takeuchi; Yuichi Aita; Takashi Matsuzaka; Hitoshi Iwasaki; Shigeru Yatoh; Motohiro Sekiya; Naoya Yahagi; Hiroaki Suzuki; Hirohito Sone; Yoshimi Nakagawa; Nobuhiro Yamada; Hitoshi Shimano
Journal:  Mol Metab       Date:  2016-09-17       Impact factor: 7.422

7.  CREB3L3 controls fatty acid oxidation and ketogenesis in synergy with PPARα.

Authors:  Yoshimi Nakagawa; Aoi Satoh; Hitomi Tezuka; Song-Iee Han; Kenta Takei; Hitoshi Iwasaki; Shigeru Yatoh; Naoya Yahagi; Hiroaki Suzuki; Yasumasa Iwasaki; Hirohito Sone; Takashi Matsuzaka; Nobuhiro Yamada; Hitoshi Shimano
Journal:  Sci Rep       Date:  2016-12-16       Impact factor: 4.379

8.  Bioenergetic cues shift FXR splicing towards FXRα2 to modulate hepatic lipolysis and fatty acid metabolism.

Authors:  Jorge C Correia; Julie Massart; Jan Freark de Boer; Margareta Porsmyr-Palmertz; Vicente Martínez-Redondo; Leandro Z Agudelo; Indranil Sinha; David Meierhofer; Vera Ribeiro; Marie Björnholm; Sascha Sauer; Karin Dahlman-Wright; Juleen R Zierath; Albert K Groen; Jorge L Ruas
Journal:  Mol Metab       Date:  2015-09-26       Impact factor: 7.422

9.  β-TrCP-mediated ubiquitination and degradation of liver-enriched transcription factor CREB-H.

Authors:  Yun Cheng; Wei-Wei Gao; Hei-Man Vincent Tang; Jian-Jun Deng; Chi-Ming Wong; Chi-Ping Chan; Dong-Yan Jin
Journal:  Sci Rep       Date:  2016-03-31       Impact factor: 4.379

10.  Hyperlipidemia and hepatitis in liver-specific CREB3L3 knockout mice generated using a one-step CRISPR/Cas9 system.

Authors:  Yoshimi Nakagawa; Fusaka Oikawa; Seiya Mizuno; Hiroshi Ohno; Yuka Yagishita; Aoi Satoh; Yoshinori Osaki; Kenta Takei; Takuya Kikuchi; Song-Iee Han; Takashi Matsuzaka; Hitoshi Iwasaki; Kazuto Kobayashi; Shigeru Yatoh; Naoya Yahagi; Masaaki Isaka; Hiroaki Suzuki; Hirohito Sone; Satoru Takahashi; Nobuhiro Yamada; Hitoshi Shimano
Journal:  Sci Rep       Date:  2016-06-13       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.